Immunological Diagnostics

We aim at developing and evaluating new diagnostic, prognostic and therapeutic approaches for paediatric leukaemias using high-end multi-colour flow cytometry.

Biology of Leukaemias

Prof. Renate Panzer-Grümayer, MD
We are trying to understand why and how leukaemia evolves and use our knowledge to improve treatment and advance cure of affected children.

Genetics of Leukaemias

Sabine Strehl, PhD
Tracking down the faulty genes that cause leukaemia with the ultimate goal to establish predictive biomarkers for the optimisation of risk-adapted therapy.

Tumour Biology

Assoc. Prof. Peter F. Ambros, PhD
We aim to establish, validate and apply new diagnostic and therapeutic tools to facilitate personalised treatment of children with malignant tumours.

Molecular Biology of Solid Tumours

Prof. Heinrich Kovar, PhD
To increase therapeutic efficacy while decreasing side effects, we have to specifically target the Achille`s heel of the disease.

Development of Cellular Therapeutics

Prof. Wolfgang Holter, MD
Our group focuses on the development of therapeutic strategies based on T cells modified with chimeric antigen receptors (CARs). 

Tumour Immunology

Alexander Dohnal, PhD
The last decades brought enormous progress in our understanding of the cellular and molecular biology of cancerous disease. One of the areas of hope is cancer immune therapy. We work on concepts for manipulating the immune system in order to trigger anti-tumour immunity, which has the capacity to control the growth of cancer cells.  

Clinical Cell Biology and FACS Core Unit

Assoc. Prof. Gerhard Fritsch, PhD
With our engagement in flow cytometry and GMP-compliant work, we are a supportive interface between research and therapy.  

Molecular Microbiology

Prof. Thomas Lion, MD, PhD
Our group primarily focuses on the improvement of treatment outcomes, particularly in transplant recipients and patients with life-threatening infections, by developing and implementing new diagnostic technologies.  

Studies & Statistics for Integrated Research and Projects

Prof. Ruth Ladenstein, MD, MBA, cPM
Multinational networking is fundamental for clinical research of malignant cancer in children and adolescents. Only controlled large-scale clinical trials allow improving complex treatment strategies, whilst smaller studies allow testing innovative drug medications to further improve survival rates. The clinical trail unit S2IRP undertakes all efforts to serve the complex tasks of clinical trial management. 

Innovative cancer models

Martin Distel, PhD
Our research focus is on the generation of pediatric cancer models in zebrafish to better understand tumor initiation and tumor progression on a cellular and molecular level.